<DOC>
	<DOCNO>NCT02934204</DOCNO>
	<brief_summary>Consolidation treatment Primary Central Nervous System Diffuse Large B cell Lymphoma ( PCNSL ) patient remain defined.Here design tolerated treatment HDMTX plus Temozolomide , follow consolidation Temozolomide PCNSL patient .</brief_summary>
	<brief_title>Temozolomide Treatment Patients With Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>( 1 ) histology confirm PCNSL . ( 2 ) lymphoma invasion brain , meninges , cerebrospinal fluid , eye organ . ( 3 ) ECOG score less 3 point ( 4 ) least 1 lesion evaluate double diameter . ( 5 ) life expectancy 6 month . ( 6 ) less equal 75 year , equal 18 year . ( 7 ) able comply requirement study followup procedure . ( 8 ) sign consent form participate study . ( 9 ) adequate organ function , define follow : Liver function , serum aspartate aminotransferase ( AST ) serum alanine aminotransferase ( ALT ) equal less 2 time upper limit normal ( ULN ) . Bone marrow function : absolute neutrophil count equal 1500/L , platelet count 100000/L , hemoglobin great 9 g/dL . Renal function , serum creatinine creatinine clearance rate ( le 1.5ULN CockcroftGault formula base improvement 50ml/min ) . ( 10 ) woman childbearing potential must start get test result serum / urine pregnancy test negative within 48 hour prior study . Postmenopausal woman least 12 month menopause treat non fertile . ( 1 ) patient history malignancy within five year ( except full treatment cervical carcinoma situ basal cell carcinoma squamous cell skin cancer ) . ( 2 ) previously treat total cranial irradiation . ( 3 ) upper digestive tract lack physical integrity , suffer malabsorption syndrome , oral drug , active gastric ulcer . ( 4 ) suffer unstable systemic disease ( include active infection , significant cardiovascular disease , significant liver kidney metabolic disorder ) , metabolic disorder , physical examination result laboratory examination result contraindication use drug , may affect treatment result interpretation increase risk complication treatment risk ( 5 ) patient human immunodeficiency virus ( HIV ) transmit form blood body fluid . ( 6 ) woman pregnancy lactation . ( 7 ) woman childbearing age want use contraceptive measure study period sexual capacity men . ( 8 ) patient want sign inform consent . ( 9 ) patient willing follow . ( 10 ) drug excipients allergy . Exit case : matter reason patient withdraw study case time postpone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>PCNSL</keyword>
	<keyword>DLBCL</keyword>
	<keyword>methotrexate</keyword>
	<keyword>temozolomide</keyword>
</DOC>